Status
Conditions
About
One aims to devise a method for the screening and differentiation of intestinal tuberculosis and Crohn's Disease. Additionally, one aims to detect and survey multidrug resistant TB.
Full description
Intestinal tuberculosis (ITB) and Crohn's disease (CD) may present identically; the consequence of misdiagnosing and mistreating one disease for the other may be grave. CD is on the increase worldwide while TB re-emerges in areas of low TB endemicity. Current diagnostic guidelines evolve from research in areas with low TB prevalence, thereby being inappropriate in TB endemic regions. To date, no simple or non-invasive methods exist to diagnose ITB and to differentiate it from CD.
One aims to devise a method for screening and differentiation of the two diseases. By using non-invasive rapid tests one wishes to make diagnostics available to resource poor settings. Ideally, referrals to invasive diagnostic procedures would decrease, thus liberating economic and staff resources. Furthermore, patients may avoid unnecessary, expensive and often inconclusive advanced procedures. Additionally, one aims to detect and survey multidrug resistance caused by empiric TB treatment, which in itself obscures ITB diagnosis.
This case control study matches 50 ITB patients and 50 CD patients with 100 healthy controls in India, and 50 CD patients with 100 healthy controls in Norway. Comparative statistical analysis will be carried out. Challenges include patient adherence and sample handling. Non-TB gastrointestinal infections may confound the results and will be adjusted for.
Recently published data suggests that the serum/faecal calprotectin ratio may be used to discriminate ITB from healthy subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Above 18 years of age.
ITB as per standard criteria a), and one or more of b) to e) must be fulfilled (Gold standard):
Active Crohn's disease as per standard criteria (Gold standard), at least two of the following:
Exclusion criteria
a) Age below 18 years b) HIV positive c) Malignancy
550 participants in 6 patient groups
Loading...
Central trial contact
Geir larsson, M.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal